Quarterly report · Q1
7733.TEDINET S100RLNN
Period2023-04-01 → 2023-06-30
Filed2023-08-09
StandardIFRS
ConsolidatedYes
Data checks10 of 10 passed
Key figures · 47
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥207.7bn | 2023-04-01 → 2023-06-30 | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥881.9bn | 2022-04-01 → 2023-03-31 | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥192.3bn | 2022-04-01 → 2022-06-30 | Cons. | Revenue IFRS (5-year summary) |
| Operating income | ¥22.5bn | 2023-04-01 → 2023-06-30 | Cons. | Operating profit loss IFRS |
| Operating income | ¥44.5bn | 2022-04-01 → 2022-06-30 | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥19.7bn | 2023-04-01 → 2023-06-30 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥182.3bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥42.0bn | 2022-04-01 → 2022-06-30 | Cons. | Profit loss before tax IFRS |
| Net income (owners) | ¥240.6bn | 2023-04-01 → 2023-06-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥143.4bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥24.9bn | 2022-04-01 → 2022-06-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income | ¥240.6bn | 2023-04-01 → 2023-06-30 | Cons. | Profit loss IFRS |
| Net income | ¥24.9bn | 2022-04-01 → 2022-06-30 | Cons. | Profit loss IFRS |
| Total assets | ¥1.69T | at 2023-06-30 | Cons. | Assets IFRS |
| Total assets | ¥1.51T | at 2023-03-31 | Cons. | Assets IFRS |
| Total assets | ¥1.43T | at 2022-06-30 | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥781.3bn | at 2023-06-30 | Cons. | Liabilities IFRS |
| Total liabilities | ¥867.1bn | at 2023-03-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥906.9bn | at 2023-06-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥641.2bn | at 2023-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥582.2bn | at 2022-06-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥511.4bn | at 2022-03-31d | Cons. | Equity IFRS |
| Equity (owners) | ¥905.9bn | at 2023-06-30 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥640.1bn | at 2023-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥581.1bn | at 2022-06-30 | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥558.7bn | at 2023-06-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥169.3bn | at 2023-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥205.5bn | at 2023-03-31 | Cons. | Cash and cash equivalents IFRS (5-year summary) |
| Cash & equivalents | ¥286.4bn | at 2022-06-30 | Cons. | Cash and cash equivalents IFRS (5-year summary) |
| Operating cash flow | −¥53.1bn | 2023-04-01 → 2023-06-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥98.5bn | 2022-04-01 → 2023-03-31 | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | −¥26.9bn | 2022-04-01 → 2022-06-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Investing cash flow | ¥427.0bn | 2023-04-01 → 2023-06-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥58.4bn | 2022-04-01 → 2023-03-31 | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | ¥5.2bn | 2022-04-01 → 2022-06-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Financing cash flow | −¥25.9bn | 2023-04-01 → 2023-06-30 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥143.2bn | 2022-04-01 → 2023-03-31 | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥21.7bn | 2022-04-01 → 2022-06-30 | Cons. | Net cash provided by used in financing activities IFRS |
| EPS (basic) | ¥191.9 | 2023-04-01 → 2023-06-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥113.22 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥19.53 | 2022-04-01 → 2022-06-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (diluted) | ¥191.5 | 2023-04-01 → 2023-06-30 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥113.08 | 2022-04-01 → 2023-03-31 | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥19.52 | 2022-04-01 → 2022-06-30 | Cons. | Diluted earnings loss per share IFRS |
| Equity ratio | 53.7% | at 2023-06-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 42.4% | at 2023-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 40.5% | at 2022-06-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 10
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2023-06-30 | −¥9.2bn |
| jpcrp040300-q1r_E02272-000Endoscopic Solutionsreportable segment | segment profit | 2023-04-01 → 2023-06-30 | ¥22.2bn |
| jpcrp040300-q1r_E02272-000Otherreportable segment | segment profit | 2023-04-01 → 2023-06-30 | −¥141m |
| jpcrp040300-q1r_E02272-000Therapeutic Solutionsreportable segment | segment profit | 2023-04-01 → 2023-06-30 | ¥9.7bn |
| —segment total | segment profit | 2023-04-01 → 2023-06-30 | ¥31.7bn |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-06-30 | ¥6.6bn |
| jpcrp040300-q1r_E02272-000Endoscopic Solutionsreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥24.8bn |
| jpcrp040300-q1r_E02272-000Otherreportable segment | segment profit | 2022-04-01 → 2022-06-30 | −¥296m |
| jpcrp040300-q1r_E02272-000Therapeutic Solutionsreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥13.4bn |
| —segment total | segment profit | 2022-04-01 → 2022-06-30 | ¥37.9bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 629
| Item | Context | Value | Unit |
|---|---|---|---|
| Intersegment sales IFRS | CurrentYTDDuration_ReconcilingItemsMember | -36000000 | JPY |
| Intersegment sales IFRS | CurrentYTDDuration | － | JPY |
| Net sales IFRS | CurrentYTDDuration_jpcrp040300-q1r_E02272-000EndoscopicSolutionsReportableSegmentMember | 127138000000 | JPY |
| Net sales IFRS | CurrentYTDDuration_jpcrp040300-q1r_E02272-000TherapeuticSolutionsReportableSegmentMember | 77156000000 | JPY |
| Net sales IFRS | CurrentYTDDuration_jpcrp040300-q1r_E02272-000OtherReportableSegmentMember | 3465000000 | JPY |
| Net sales IFRS | CurrentYTDDuration_ReportableSegmentsMember | 207759000000 | JPY |
| Net sales IFRS | CurrentYTDDuration_ReconcilingItemsMember | -36000000 | JPY |
| Net sales IFRS | CurrentYTDDuration | 207723000000 | JPY |
| Operating profit loss IFRS | CurrentYTDDuration_jpcrp040300-q1r_E02272-000EndoscopicSolutionsReportableSegmentMember | 22177000000 | JPY |
| Operating profit loss IFRS | CurrentYTDDuration_jpcrp040300-q1r_E02272-000TherapeuticSolutionsReportableSegmentMember | 9681000000 | JPY |
| Operating profit loss IFRS | CurrentYTDDuration_jpcrp040300-q1r_E02272-000OtherReportableSegmentMember | -141000000 | JPY |
| Operating profit loss IFRS | CurrentYTDDuration_ReportableSegmentsMember | 31717000000 | JPY |
| Operating profit loss IFRS | CurrentYTDDuration_ReconcilingItemsMember | -9241000000 | JPY |
| Operating profit loss IFRS | CurrentYTDDuration | 22476000000 | JPY |
| Finance income IFRS | CurrentYTDDuration | 521000000 | JPY |
| Finance costs IFRS | CurrentYTDDuration | 3287000000 | JPY |
| Profit loss before tax IFRS | CurrentYTDDuration | 19710000000 | JPY |
| Share of profit loss of investments accounted for using equity method IFRS | CurrentYTDDuration_jpcrp040300-q1r_E02272-000EndoscopicSolutionsReportableSegmentMember | -184000000 | JPY |
| Share of profit loss of investments accounted for using equity method IFRS | CurrentYTDDuration_jpcrp040300-q1r_E02272-000TherapeuticSolutionsReportableSegmentMember | -5000000 | JPY |
| Share of profit loss of investments accounted for using equity method IFRS | CurrentYTDDuration_jpcrp040300-q1r_E02272-000OtherReportableSegmentMember | － | JPY |
| Share of profit loss of investments accounted for using equity method IFRS | CurrentYTDDuration_ReportableSegmentsMember | -189000000 | JPY |
| Share of profit loss of investments accounted for using equity method IFRS | CurrentYTDDuration_ReconcilingItemsMember | － | JPY |
| Share of profit loss of investments accounted for using equity method IFRS | CurrentYTDDuration | -189000000 | JPY |
| Depreciation and amortization operating expenses IFRS | CurrentYTDDuration_jpcrp040300-q1r_E02272-000EndoscopicSolutionsReportableSegmentMember | 10276000000 | JPY |
| Depreciation and amortization operating expenses IFRS | CurrentYTDDuration_jpcrp040300-q1r_E02272-000TherapeuticSolutionsReportableSegmentMember | 4683000000 | JPY |
| Depreciation and amortization operating expenses IFRS | CurrentYTDDuration_jpcrp040300-q1r_E02272-000OtherReportableSegmentMember | 245000000 | JPY |
| Depreciation and amortization operating expenses IFRS | CurrentYTDDuration_ReportableSegmentsMember | 15204000000 | JPY |
| Depreciation and amortization operating expenses IFRS | CurrentYTDDuration_ReconcilingItemsMember | 1409000000 | JPY |
| Depreciation and amortization operating expenses IFRS | CurrentYTDDuration | 16613000000 | JPY |
| Impairment losses pl IFRS | CurrentYTDDuration_jpcrp040300-q1r_E02272-000EndoscopicSolutionsReportableSegmentMember | 138000000 | JPY |
| Impairment losses pl IFRS | CurrentYTDDuration_jpcrp040300-q1r_E02272-000TherapeuticSolutionsReportableSegmentMember | － | JPY |
| Impairment losses pl IFRS | CurrentYTDDuration_jpcrp040300-q1r_E02272-000OtherReportableSegmentMember | － | JPY |
| Impairment losses pl IFRS | CurrentYTDDuration_ReportableSegmentsMember | 138000000 | JPY |
| Impairment losses pl IFRS | CurrentYTDDuration_ReconcilingItemsMember | -4000000 | JPY |
| Impairment losses pl IFRS | CurrentYTDDuration | 134000000 | JPY |
| Document title cover page | FilingDateInstant | Original text (Japanese)四半期報告書 | |
| Clause of stipulation cover page | FilingDateInstant | Original text (Japanese)金融商品取引法第24条の４の７第１項 | |
| Place of filing cover page | FilingDateInstant | Original text (Japanese)関東財務局長 | |
| Filing date cover page | FilingDateInstant | 2023-08-09 | |
| Quarterly accounting period cover page | FilingDateInstant | Original text (Japanese)第156期(2024年３月期)第１四半期（自 2023年４月１日 至 2023年６月30日） | |
| Company name cover page | FilingDateInstant | Original text (Japanese)オリンパス株式会社 | |
| Company name in english cover page | FilingDateInstant | OLYMPUS CORPORATION | |
| Title and name of representative cover page | FilingDateInstant | Original text (Japanese)取締役 代表執行役 社長兼CEO シュテファン・カウフマン | |
| Address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)東京都八王子市石川町2951番地 | |
| Telephone number address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)東京3340局2111番(代表) | |
| Name of contact person address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)経理部門バイスプレジデント 青柳 隆之 | |
| Nearest place of contact cover page | FilingDateInstant | Original text (Japanese)東京都新宿区西新宿２丁目３番１号 新宿モノリス | |
| Telephone number nearest place of contact cover page | FilingDateInstant | Original text (Japanese)東京3340局2111番(代表) | |
| Name of contact person nearest place of contact cover page | FilingDateInstant | Original text (Japanese)IR部門バイスプレジデント 櫻井 隆明 | |
| Place for public inspection cover page (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 10 of 10 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |